SGTX—How bad the clinical hold is depends on the cause of the FVII inhibitors seen in the patient who received the highest dose tested so far. From yesterday’s PR:
If the development of inhibitors in this patient is deemed to be drug-related, that’s a pretty bad outcome for SGTX. At a minimum, the dose for future testing will probably have to be kept lower than the dose in question, thereby lowering efficacy.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.